Form 4 for PCVX Vaxcyte, Inc.
Accepted 2023-06-09 00:00:00 ET · period of report 2023-06-07 · accession 0001209191-23-035854 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-09 | 2023-06-07 | PCVX | Eydelman Mikhail | SVP, Gen Counsel, Corp Sec | F - Tax | $51.25 | -645 | 21.7K | -3% | -$33.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-07 | F | D | 645 | $51.25 | 21,676 | D | — | — | (F1) Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. (F2) Includes 539 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on May 17, 2023. |